Literature DB >> 16857731

Determining the potency and molecular mechanism of action of insurmountable antagonists.

Terry Kenakin1, Stephen Jenkinson, Christian Watson.   

Abstract

Insurmountable antagonism (maximal response to the agonist depressed) can result from a temporal inequilibrium involving a slow offset orthosteric antagonist or be the result of an allosteric modulation of the receptor. The former mechanism is operative when the antagonist, agonist, and receptors cannot come to proper equilibrium during the time allotted for collection of agonist response (hemi-equilibrium conditions). Allosteric effects (changes in the conformation of the receptor through binding of the allosteric modulator to a separate site) can preclude the agonist-induced production of response, leading to depression of maximal responses. In these cases, the effects on receptor affinity can be observed as well. The first premise of this article is that system-independent estimates of insurmountable antagonist potency can be made with no prior knowledge of molecular mechanism through the use of pA(2) (-log molar concentration of antagonist producing a 2-fold shift of the concentration response curve) measurements The relationship between the pA(2) and antagonist pK(B) (-log equilibrium dissociation constant of the antagonist-receptor complex) is described; the former is an extremely close approximation of the latter in most cases. The second premise is that specially designed experiments are required to differentiate orthosteric versus allosteric mechanisms; simply fitting of data to orthosteric or allosteric theoretical models can lead to ambiguous results. A strategy to determine whether the observed antagonism is orthosteric (agonist and antagonist competing for the same binding site on the receptor) or allosteric in nature is described that involves the detection of the hallmarks of allosteric response, namely saturation and probe dependence of effect.

Entities:  

Mesh:

Year:  2006        PMID: 16857731     DOI: 10.1124/jpet.106.107375

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  46 in total

1.  Modulation of bitter taste perception by a small molecule hTAS2R antagonist.

Authors:  Jay P Slack; Anne Brockhoff; Claudia Batram; Susann Menzel; Caroline Sonnabend; Stephan Born; Maria Mercedes Galindo; Susann Kohl; Sophie Thalmann; Liliana Ostopovici-Halip; Christopher T Simons; Ioana Ungureanu; Kees Duineveld; Cristian G Bologa; Maik Behrens; Stefan Furrer; Tudor I Oprea; Wolfgang Meyerhof
Journal:  Curr Biol       Date:  2010-05-27       Impact factor: 10.834

Review 2.  Elusive equilibrium: the challenge of interpreting receptor pharmacology using calcium assays.

Authors:  Steven J Charlton; Georges Vauquelin
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

Review 3.  Use of the GTPγS ([35S]GTPγS and Eu-GTPγS) binding assay for analysis of ligand potency and efficacy at G protein-coupled receptors.

Authors:  Philip G Strange
Journal:  Br J Pharmacol       Date:  2010-11       Impact factor: 8.739

Review 4.  Long-lasting target binding and rebinding as mechanisms to prolong in vivo drug action.

Authors:  Georges Vauquelin; Steven J Charlton
Journal:  Br J Pharmacol       Date:  2010-10       Impact factor: 8.739

Review 5.  On the different experimental manifestations of two-state 'induced-fit' binding of drugs to their cellular targets.

Authors:  Georges Vauquelin; Isabelle Van Liefde; David C Swinney
Journal:  Br J Pharmacol       Date:  2016-03-15       Impact factor: 8.739

Review 6.  Escaping the flatlands: new approaches for studying the dynamic assembly and activation of GPCR signaling complexes.

Authors:  Thomas Huber; Thomas P Sakmar
Journal:  Trends Pharmacol Sci       Date:  2011-04-15       Impact factor: 14.819

7.  What systems can and can't do.

Authors:  T Kenakin
Journal:  Br J Pharmacol       Date:  2008-01-21       Impact factor: 8.739

Review 8.  Allosteric modulators of g protein-coupled receptors: future therapeutics for complex physiological disorders.

Authors:  Liyun Wang; Bronwen Martin; Randall Brenneman; Louis M Luttrell; Stuart Maudsley
Journal:  J Pharmacol Exp Ther       Date:  2009-08-10       Impact factor: 4.030

9.  Isolation and pharmacological characterization of AdTx1, a natural peptide displaying specific insurmountable antagonism of the alpha1A-adrenoceptor.

Authors:  L Quinton; E Girard; A Maiga; M Rekik; P Lluel; G Masuyer; M Larregola; C Marquer; J Ciolek; T Magnin; R Wagner; J Molgó; R Thai; C Fruchart-Gaillard; G Mourier; J Chamot-Rooke; A Ménez; S Palea; D Servent; N Gilles
Journal:  Br J Pharmacol       Date:  2009-12-15       Impact factor: 8.739

10.  Differential interactions of the catalytic subunits of adenylyl cyclase with forskolin analogs.

Authors:  Cibele Pinto; Melanie Hübner; Andreas Gille; Mark Richter; Tung-Chung Mou; Stephen R Sprang; Roland Seifert
Journal:  Biochem Pharmacol       Date:  2009-04-02       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.